A new trading day began on Friday, with Gain Therapeutics Inc (NASDAQ: GANX) stock price down -34.39% from the previous day of trading, before settling in for the closing price of $1.89. GANX’s price has ranged from $1.80 to $5.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 93.18%. Meanwhile, its annual earnings per share averaged 38.95%. With a float of $16.83 million, this company’s outstanding shares have now reached $18.05 million.
The extent of productivity of a business whose workforce counts for 32 workers is very important to gauge.
Gain Therapeutics Inc (GANX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Gain Therapeutics Inc is 6.75%, while institutional ownership is 10.35%. The most recent insider transaction that took place on Mar 28 ’24, was worth 115,770. In this transaction Director of this company bought 30,000 shares at a rate of $3.86, taking the stock ownership to the 30,000 shares. Before that another transaction happened on Dec 21 ’23, when Company’s Chief Executive Officer sold 206 for $2.46, making the entire transaction worth $507. This insider now owns 5,286 shares in total.
Gain Therapeutics Inc (GANX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 38.95% per share during the next fiscal year.
Gain Therapeutics Inc (NASDAQ: GANX) Trading Performance Indicators
Here are Gain Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -1.10 in one year’s time.
Technical Analysis of Gain Therapeutics Inc (GANX)
The latest stats from [Gain Therapeutics Inc, GANX] show that its last 5-days average volume of 0.86 million was superior to 0.18 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 7.56%. Additionally, its Average True Range was 0.32.
During the past 100 days, Gain Therapeutics Inc’s (GANX) raw stochastic average was set at 0.24%, which indicates a significant decrease from 0.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 194.85% in the past 14 days, which was higher than the 97.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.7336, while its 200-day Moving Average is $3.2758. Now, the first resistance to watch is $1.3900. This is followed by the second major resistance level at $1.5400. The third major resistance level sits at $1.6200. If the price goes on to break the first support level at $1.1600, it is likely to go to the next support level at $1.0800. Assuming the price breaks the second support level, the third support level stands at $0.9300.
Gain Therapeutics Inc (NASDAQ: GANX) Key Stats
With a market capitalization of 22.38 million, the company has a total of 18,052K Shares Outstanding. Currently, annual sales are 60 K while annual income is -22,270 K. The company’s previous quarter sales were 0 K while its latest quarter income was -4,010 K.
